Daklinza 30 mg Oral Tablet
RxNorm 1660191

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1660191 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Daklinza 30 mg Oral Tablet.

The following semantic concepts and normalized strings are associated with this clinical entity:

SY
Daclatasvir 30 mg (as daclatasvir dihydrochloride 33 mg) Oral Tablet [Daklinza]
AUI:8230228
View
SBD
Daclatasvir 30 mg Oral Tablet [Daklinza]
AUI:7256218
View
PSN
Daklinza 30 mg Oral Tablet
AUI:7256230
View
SY
Daklinza 30 mg Oral Tablet
AUI:7256219
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SY

Synonym (SY):
Daclatasvir 30 mg (as daclatasvir dihydrochloride 33 mg) Oral Tablet [Daklinza]
(Atom ID: 8230228)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
daclatasvir 30 MG (as daclatasvir dihydrochloride 33 mg) Oral Tablet [Daklinza]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1660191
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
8230228
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1660191
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SBD

Semantic Branded Drug (SBD):
Daclatasvir 30 mg Oral Tablet [Daklinza]
(Atom ID: 7256218)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
daclatasvir 30 MG Oral Tablet [Daklinza]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1660191
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
7256218
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
1660191
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{1660181} 1606217
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{1660181} 1606218
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{1660181} AM
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN OBSOLETED
06/29/2022
Date the RxNorm atom became obsolete
RXTERM FORM
Tab
The RxTerm dose form name for this drug
PSN

Prescribable Name (PSN):
Daklinza 30 mg Oral Tablet
(Atom ID: 7256230)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Daklinza 30 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1660191
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
7256230
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1660191
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SY

Synonym (SY):
Daklinza 30 mg Oral Tablet
(Atom ID: 7256219)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Daklinza 30 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1660191
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
7256219
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1660191
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Daclatasvir


Daclatasvir is used along with another medication (sofosbuvir [Solvadi]) to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body. It is not known if daclatasvir prevents the spread of hepatitis C to other people.
[Learn More]


* Please review the disclaimer below.